Abstract
Objectives Adequate antiretroviral drug distribution into the female genital tract (FGT) could play an important role in reducing the risk of heterosexual and mother-to-child transmission of HIV. In this study, we investigated the combined influence of pregnancy and genetic polymorphisms on efavirenz pharmacokinetics in cervicovaginal fluid (CVF) of women receiving antiretroviral therapy.
Methods A total of 159 women (147 pregnant and 12 postpartum) living with HIV and receiving efavirenz-containing antiretroviral therapy were recruited across two sites in Nigeria (Federal Medical Centre, and Bishop Murray Medical Centre, Makurdi) between 2017-2020. In stage 1, sparse CVF and dried blood spot (DBS) samples were obtained from each participant during pregnancy to assess possible association between drug concentration and CYP2B6 polymorphisms (516G>T and 983 T>C). In the second stage, participants were stratified into three genotype groups (extensive, intermediate and low metabolisers) and re-enrolled for intensive pharmacokinetic sampling.
Results In stage 1 (88 CVF, 81 plasma and 73 paired samples), CYP2B6 516G>T was independently associated with both CVF (β = 997 ng/mL (90% CI: 598, 1357), p = 5.7 x 10-5) and plasma (β = 1400 ng/mL (90% CI: 1051, 1748), p = 5.7 x 10-9) efavirenz concentration during pregnancy. In the second stage (12 pregnant, 12 postpartum), median (IQR) efavirenz Cmin in CVF during pregnancy versus postpartum was 243 ng/ml (168-402) vs 447 ng/ml (159-974), Cmax was 1031 ng/ml (595-1771) vs 1618 ng/ml (675-2695), and AUC0-24 was 16465 ng.h/ml (9356-30417) vs 30715 ng.h/ml (10980-43714). Overall, median CVF-to-plasma AUC ratio was 0.34 during pregnancy and 0.46 postpartum. When patients were stratified using CYP2B6 516G>T, efavirenz median clearance increased by 57.9% during pregnancy compared with postpartum control (p = 0.232) in patients with the CYP2B6 516GT genotype. The AUC0-24h, Cmax and Cmin reduced by 33.8% ((p=0.182), 8.6% (0.175) and 59.5% (0.171) during pregnancy, with values of 20671 ng.h/ml (15993-28712), 1550 ng/ml (1090-2090) and 330 ng/ml (250-440), respectively, compared with 31229 ng.h/ml (27660-41873), 1695 ng/ml (1540-3003) and 814 ng/ml (486-981) during postpartum in this genotype.
Median efavirenz Cmin in CVF was 1.93 and 3.55 times higher than the PBIC90 of 126 ng/ml in the pregnant and postpartum cohorts, respectively.
Conclusions Efavirenz is well distributed into the CVF, and both pregnancy and polymorphisms in its disposition genes affect CVF exposure.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03284645
Clinical Protocols
https://wellcomeopenresearch.org/articles/4-34
Funding Statement
This work was supported in whole, or in part, by the Wellcome Trust International Training Fellowship to Adeniyi Olagunju (204776/Z/16/Z). The funder played no role in study design, data collection and analysis, decision, preparation of the manuscript or decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the National Health Research Ethics Committee, Abuja, Nigeria gave ethical approval for this work (approval number: NHREC/01/01/2007-05/06/2017).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest: None to declare.
Source of funding: This work was supported in whole, or in part, by the Wellcome Trust International Training Fellowship to Adeniyi Olagunju (204776/Z/16/Z). The funder played no role in study design, data collection and analysis, decision, preparation of the manuscript or decision to publish.
Data Availability
All data produced in the present study are available upon reasonable request to the author
